Lichen Planopilaris
13
3
3
8
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
0.0%
0 terminated out of 13 trials
100.0%
+13.5% vs benchmark
15%
2 trials in Phase 3/4
50%
4 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (13)
A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris
Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilaris
Nemolizumab to Treat Lichen Planopilaris, a Noncontrolled, Prospective, Pilot Study.
A Study of Deucravacitinib to Treat LPP and FFA
The Effectiveness of Hydroxychloroquine Versus Methotrexate in the Treatment of Lichen Planopilaris in Routine Clinical Care: a Patient Preference Trial
a Retrospective Study on the Systemic Treatment of LPP and FFA
Ixekizumab in Adult Patients With Lichen Planus and Lichen Planopilaris
Role of Neurogenic Inflammation and Topical 6% Gabapentin Therapy in Symptomatic Scarring Alopecia
Design and Validation of a New Assessment Tool for Lichen Planopilaris
Oral Low-Dose Naltrexone for Lichen Planopilaris and Frontal Fibrosing Alopecia
Pain Outcomes Following Intralesional Corticosteroid Injections
Valchlor in the Treatment of Lichen Planopilaris
Expression of Fas Protein in Skin Biopsies of Participants With Scarring Alopecia